Lucid Diagnostics Stock Price To Earning
| LUCD Stock | USD 1.29 0.04 3.20% |
Fundamental analysis of Lucid Diagnostics allows traders to better anticipate movements in Lucid Diagnostics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Lucid | Price To Earning | Build AI portfolio with Lucid Stock |
Lucid Diagnostics Company Price To Earning Analysis
Lucid Diagnostics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Lucid Price To Earning Driver Correlations
Understanding the fundamental principles of building solid financial models for Lucid Diagnostics is extremely important. It helps to project a fair market value of Lucid Stock properly, considering its historical fundamentals such as Price To Earning. Since Lucid Diagnostics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lucid Diagnostics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lucid Diagnostics' interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Lucid Retained Earnings
Retained Earnings |
|
Based on the latest financial disclosure, Lucid Diagnostics has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The price to earning for all United States stocks is 100.0% higher than that of the company.
Lucid Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lucid Diagnostics' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lucid Diagnostics could also be used in its relative valuation, which is a method of valuing Lucid Diagnostics by comparing valuation metrics of similar companies.Lucid Diagnostics is currently under evaluation in price to earning category among its peers.
Lucid Diagnostics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Lucid Diagnostics from analyzing Lucid Diagnostics' financial statements. These drivers represent accounts that assess Lucid Diagnostics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lucid Diagnostics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 434.9M | 133.9M | 28.7M | 55.2M | (1.1B) | (1.0B) |
Lucid Fundamentals
| Return On Equity | -29.56 | ||||
| Return On Asset | -0.99 | ||||
| Operating Margin | (10.26) % | ||||
| Current Valuation | 164.9 M | ||||
| Shares Outstanding | 105.13 M | ||||
| Shares Owned By Insiders | 35.92 % | ||||
| Shares Owned By Institutions | 4.74 % | ||||
| Number Of Shares Shorted | 1.6 M | ||||
| Price To Book | 2.16 X | ||||
| Price To Sales | 31.08 X | ||||
| Revenue | 4.35 M | ||||
| Gross Profit | (2.75 M) | ||||
| EBITDA | (44.34 M) | ||||
| Net Income | (45.53 M) | ||||
| Cash And Equivalents | 34.46 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 21.25 B | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 4.55 X | ||||
| Book Value Per Share | (0.78) X | ||||
| Cash Flow From Operations | (44.14 M) | ||||
| Short Ratio | 1.13 X | ||||
| Earnings Per Share | (1.05) X | ||||
| Target Price | 3.75 | ||||
| Number Of Employees | 72 | ||||
| Beta | 1.26 | ||||
| Market Capitalization | 135.09 M | ||||
| Total Asset | 30.71 M | ||||
| Retained Earnings | (203.77 B) | ||||
| Working Capital | 1.62 M | ||||
| Net Asset | 30.71 M |
About Lucid Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lucid Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lucid Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lucid Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:Check out Lucid Diagnostics Piotroski F Score and Lucid Diagnostics Altman Z Score analysis. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share | Quarterly Revenue Growth 0.151 | Return On Assets | Return On Equity |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.